January 2009 Grants

Federal Grants

Bernstein, I.,
NIH/UT-San Antonio, Psychometric Properties and Diagnostic Utility of the Pain Descriptor System, $48,002; Bierner, S., NIH/UT-Arlington, Preventing Co-Morbid Mental and Physical Health Disability, $104,901; Cleaver, O., NIH/The Hebrew University of Jerusalem, Vascular Signals in Pancreas Development and Beta Cell Differentiation, $102,386; Diaz-Arrastia, R., NIH/University of California, San Diego, ADCS-Pfizer Clinical Trial of Rage Inhibitor in PeT Imaging of Brain Amyloid-Beta With 18F-AV-45 (Florpiramine F-18), $16,000;  Farrar, J., Type I Interferon-Regulated T Helper Development, $170,672. 

january-grants

Gazdar, A., NIH/University of Texas M.D. Anderson Cancer Center, Forerunner Genes: A Novel Class of Novel Detection Markers for Bladder Cancer, $38,217; Gerard, R., NIH, Targeted Imaging Using Adenoviral Vectors, $171,000; Goodman, J., NIH/The Trustees of Columbia University in the City of New York, Summer Immunology Research Program for High School Science Teachers, $21,377; Hamra, F., NIH, Discovery & Function of Fertilization-Specific Moleculres, $169,350; Hansen, J., NIH, Haemophilus Ducreyi Inhibits Phagocytosis, $214,324.

Herz, J.,
NIH, Metabolism of the VLDL Receptor and ApoE Receptor 2, $213,341; Inrig, J., NIH, Blood Pressure, Endothelial Cell Dysfunction and Outcomes in Dialysis Patients, $120,735; Karandikar, N., NIH, Role of T Cells in the Immune Modulation of MS, $180,000; Kodibagkar, V., NIH, 1H MRI Based Nanosensors for Imaging Tumor Oxygenation, $100,000; Kramer, H., NIH, Genetics of Endocytic Trafficking in the Eye, $225,000.

Lu, H., NIH, Quantitative Measurement of Spinal Cord Perfusion in Humans using MRI, $135,556; MacDonald, R., NIH/Vanderbilt University Medical Center, SASsy3: Signal Activated Sentinels for Beta-Cell Development and Regeneration, $106,000; Mendelson, C., NIH, Mechanisms in the Regulation of SP-A Gene Expression, $297,601; Munshi, N., NIH, Molecular Dissection of Cardiac Conduction System Development, $121,000; Parada, L., NIH, Genetic Mouse Models of Glioma, $243,284.

Pfeiffer, J., NIH, The Influence of Host Barriers on Viral Quasispecies Diversity and Pathogenesis, $180,000; Powell, C., NIH, Neuroligin Function in Vivo: Implications for Autism and Mental Retardation, $200,000; Rutherford, C., NIH/UT Health Science Center at Houston, Prevention of the Complications of Bleeding Disorders through Hemophilia Treatment; $54,547; Schneider, J., NIH, UT-Southwestern-Progenitor Cell Biology Consortium Group, $25,000; Self, D., NIH/Mount Sinai School of Medicine, Molecular Neurology of Drug Addiction: Project Three Subcontract, $45,000.

Self, D.,
NIH/Mount Sinai School of Medicine, Molecular Neurology of Drug Addiction: Project Four Subcontract, $160,000; Shad, M., NIH, Neurobiology of Insight Deficits in Schizophrenia, $156,200; Sperandio, V., NIH, Quorum Sensing Regulation of EHEC Virulence Genes, $272,048; Winick, N., NIH/CureSearch-National Childhood Cancer Foundation, Children’s Oncology Group, $33,322.

Non-Federal Awards

Brekken, R., Joan’s Legacy: Uniting Against Lung Cancer, Identification of Tumor Cell-Derived Factors Associated with Resistance to anti-VEGF Therapy in Lung Cancer, $45,455; Corey, D., The McKnight Endowment Fund for Neuroscience, Allele-Selective Inhibition of MUT-ant Huntington and Other Triplet Repeat Proteins, $90,909; Wiebe, D., Timberlawn Research Foundation, Parental Involvement in Diabetes Care Among Latino and Caucasian YoUT-h, $47,000; White, P., Juvenile Diabetes Research Foundation, Gene Expression in Peripheral Blood Leukocytes in Type 1 Diabetes Mellitus, $154,454; Wright, W., Muscular Dystrophy Association Inc., Immortal Cells for Myoblast Transfer Therapy, $90,909; Ye, J., American Heart Association, Characterization of Sterol-Regulated Degradation of Insig-1 Protein, $61,254.


Pharmaceutical Studies Awarded, Dollar Amount Not Available

Arko, F.,
Comparison of EVAR Using Study Stent-Grafts with High Density Versus Reduced-Porosity Graft Material; Collins, Jr., R., APhase 2, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Combination of Study Drug and Velcade® Versus Velcade Alone in Subjects with Relapsed or Refractory Multiple Myeloma;Collins, Jr., R., An Open-Label, Single-Arm Phase II Study of Study Drug in Patients with Refractory Mantle Cell Lymphoma; Crary, S., Von Willebrand Disease Prophylaxis Network (vWD PN): The VWD International Prophylaxis (VIP) Study.

Devous, Sr,. M., An Open Label, Parallel Group, Multicenter Study Evaluating the Safety and Imaging Characteristics of study agent in Healthy Volunteers, Patients with Mild Cognitive Impairment (MCI) and Patients with Alzheimer’s Disease (AD); Dowell, J., A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin/Paclitaxel in Combination with Study Drug Versus Carboplatin/Paclitaxel Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment; McPhaul, M., A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Study Drug vs. Octreotide LAR in Patients with Active Acromegaly; Pandya, A., Creation and Validation of a Self-Diagnostic Tool for Pigmentary Disorders among Patients with Skin of Color.

Raskin, P., APhase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Study Drug for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM); Rivas, H., Prospective Randomized Controlled Trial of Traditional Laparoscopic Cholecystectomy Versus Study Device Port Laparoscopic Cholecystectomy; Steel, K., A Prospective, Randomized-Controlled Evaluation of Nanotite and Osseotite Surfaced Implant Performance in Graduate Student Programs (“The College-Bowel Project”); Torres, F., ATHENA-1: A Randomized, Multicenter Study of Study Drug and Sildenafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension Demonstrated a Sub-Optimal Response to Sildenafil.

Wolfe, G., A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Center Study of Study Drug in Patients with Generalized Myasthenia Gravis (gMG) Who Have Moderate to Severe Muscle Weakness Despite Treatment With Immunosuppressants.

ctoexclusive

Share: